Categories AlphaGraphs, Earnings, Retail
Kohl’s Corporation reports higher Q2 profit despite a decline in sales
Kohl’s Corporation (NYSE: KSS) on Wednesday reported an increase in second-quarter 2025 earnings, despite a decrease in sales. The retailer also provided guidance for fiscal 2025.
Total revenues declined 5% year-over-year to $3.5 billion in the second quarter of fiscal 2025. Comparable store sales dropped 4.2%. The company reported net income of $153 million or $1.35 per share for the July quarter, compared to $66 million or $0.59 per share in the year-ago quarter.

Adjusted net income was $64 million or $0.56 per share in Q2. For fiscal 2025, the management expects net sales to decrease by 5-6%. Full-year earnings per share are expected to be in the range of $0.50 to $0.80, on an adjusted basis.
Michael Bender, Kohl’s Interim Chief Executive Ocer, said, “Kohl’s second quarter performance is a testament to
the progress we are making against our 2025 initiatives. This resulted in sales performance that came in ahead of
our expectations.”
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Bank of New York Mellon Corporation (BK) Earnings: 4Q25 Key Numbers
The Bank of New York Mellon Corporation (NYSE: BK) reported its fourth quarter 2025 earnings results today. Total revenue of $5.2 billion increased 7% on a year-over-year basis. Net income
Delta Air Lines (DAL) Q4 2025 Earnings: Key financials and quarterly highlights
Delta Air Lines (NYSE: DAL) reported its fourth quarter 2025 earnings results today. Total operating revenue increased 3% year-over-year to $16 billion. Net income grew 45% to $1.22 billion, or
Johnson & Johnson heads into Q4 as a more focused healthcare leader
Johnson & Johnson (NYSE: JNJ) is capitalizing on its transition from a broad-based healthcare conglomerate into a market leader in innovative medicine and medical technology. The company continues to expand



